🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “The First People's Hospital of Lianyungang” Clear

  1. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  3. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Lanthanum Polystyrene Sulphonate Powder

    The First People's Hospital of Lianyungang

    Hyperphosphatemia

    phase 2 small molecule active

    1 trial

  5. Lenalidomide

    The First People's Hospital of Lianyungang

    PTCL, NOS

    phase 2 small molecule active

    1 trial

  6. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Lenvatinib

    The First People's Hospital of Lianyungang

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  8. Lifei Qingchang Granules

    The First People's Hospital of Lianyungang

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  9. Linperlisib combination with obinutuzumab

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 2 small molecule active

    1 trial

  10. Liposomal irinotecan

    The First People's Hospital of Lianyungang

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Liposuction

    The First People's Hospital of Lianyungang

    Anterior Cruciate Ligament Partial Rupture

    phase 2 other active

    1 trial

  12. Luspatercept combined with low-dose thalidomide

    The First People's Hospital of Lianyungang

    Transfusion-dependent β-thalassemia Patients

    phase 2 small molecule active

    1 trial

  13. MB07133

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 2 small molecule active

    1 trial

  14. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  15. MenSCs transplantation

    The First People's Hospital of Lianyungang

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  16. Menstrual blood stem cells

    The First People's Hospital of Lianyungang

    Acute Lung Injury

    phase 2 small molecule active

    1 trial

  17. Methotrexate tablets

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  18. Mitoxantrone liposome

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  20. Neoadjuvant Chemotherapy (NACT)

    The First People's Hospital of Lianyungang

    HR+/HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  22. Neoadjuvant Therapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  23. Neoadjuvant therapy: TCbHPy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  24. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources